Member Directory


hans-ulrich.demuth's picture

Hans-Ulrich Demuth, PhD

Fraunhofer Institute for Cell Therapy & Immunology, Leipzig (IZI)

Contact Information

Hans-Ulrich Demuth, PhD
hans-ulrich [dot] demuth [at] izi [dot] fraunhofer [dot] de
Phone: +49 345 13142800
Halle (Saale), Germany

Professional Information

Professor & Head of Department of Drug Design & Target Validation, Halle/S. of the
Fraunhofer Institute for Cell Therapy & Immunology, Leipzig (IZI)


Academic Education and Degrees Prof. Dr. (PhD), Biochemistry 1973 – 1993 undergraduate studies of Biochemistry at Martin-Luther-University Halle-Wittenberg 1977 Diploma Biochemistry 1982 PhD Biochemistry 1990 Dr. of Sciences (habilitation) 1990 facultas docendi (teaching allowance) Professor of Pharmabiotechnology at Anhalt University of Applied Sciences, Department of Applied Biosciences


More than 35 years academic and industrial experience in target validation and drug discovery.
Research focusing on bioorganic mechanisms, enzyme-inhibition and protein-ligand interactions.
Work on proline-specific peptidases led to pioneering a drug discovery program in 1993 for the development of anti-diabetic drugs (from 1997 on is the DP4-inhibitor class on the market to treat type 2 diabetes). Since 1992 focus on proteins relevant in CNS disorders.
Results were published about 200 posters, more than 200 peer reviewed papers, and some 120 issued patents. Roughly 40 Bachelor, Master and Diploma theses and more than 30 PhD theses were prepared under my supervision.

Past Professional Positions
1993-2000 heading Dept. Drug Discovery, Hans-Knoell-Institute Jena, Germany.
1997-2013 CEO/CSO of Probiodrug AG, Halle/S. and Ingenium GmbH, Munich, Germany, a biopharmaceutical enterprise developing new therapeutics against Alzheimer's disease.

Present Professional Position
Head of the Department of Drug Design and Target Validation, Biocenter, Halle (Saale),
a subsidiary of the Leipzig-based Institute of Cell Therapy and Immunology (IZI) of the German Fraunhofer Society.
It consists of three research divisions focusing on biochemical and pharmacological target validation, molecular and cell biotechnology, drug design and bioanalytics. Main focus is target validation and drug discovery in the fields of neurodegeneration, inflammation and cancer.

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:

I inaugurated and co-founded Probiodrug AG, Halle (Saale), Germany in 1997 and assist still as CSA (Chief Scientific Advisor). I do hold stock in the company group.